Overview

This contributed book provides a comprehensive exploration of chemical and immunological strategies in cancer therapeutics, emphasizing precision medicine approaches for targeted and effective treatments. It integrates cutting-edge advancements in drug discovery, covering a diverse range of anticancer agents, from natural compounds and metal-based complexes to synthetic inhibitors and nanocarriers. The chapters cover topics such as the rational design and optimization of cancer therapeutics, employing molecular modeling, structure-activity relationship analysis, and AI-driven drug discovery. Additionally, the book highlights immunological interventions, such as immune checkpoint inhibitors and host-directed therapies, showcasing their growing relevance in personalized cancer treatment. Readers will discover diverse perspectives from expert contributing authors, offering a balanced perspective on the potential and limitations of these compounds in cancer therapeutics. This book is intended for researchers, academics, clinicians, and industry professionals engaged in oncology, pharmacology, medicinal chemistry, and natural product research. By combining theoretical insights with practical applications, it aims to advance understanding, inspire innovation, and facilitate the translation of promising cancer therapeutics from the lab to clinical settings.

Full Product Details

9789819597765

Table of Contents

Reviews

Author Information

Dr. Vibhav Gautam integrates ethnopharmacology, nanobiotechnology, and omics sciences to develop targeted cancer therapeutics, with a primary focus on breast and urinary bladder cancers. His research has led to the identification of bioactive compounds from fungal endophytes that demonstrate apoptosis-inducing activity in breast cancer models. He has also developed nanomedicine-based drug delivery systems to improve therapeutic efficacy while reducing systemic toxicity. In addition, his omics-driven studies have contributed to the identification of novel biomarkers and the advancement of personalized cancer therapy. Dr. Navin Kumar Verma completed his PhD and postdoctoral training in Clinical Medicine at Trinity College Dublin, Ireland. He is currently an Associate Professor of Immunology and Cell Biology at Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. His research focuses on T-cell immunology in wound healing and cancer. Dr. Verma has published over 100 peer-reviewed articles, holds multiple patents, and has received several national and international awards. He is an elected Fellow of the Royal Society of Biology, UK. Dr. Rajiv Kumar received his Master’s and PhD degrees in Biochemistry from Banaras Hindu University and completed postdoctoral training at QIMR Berghofer Medical Research Institute, Australia. His research focuses on cellular and molecular immunology of parasitic diseases, diagnostics, and therapeutic development. He is a member of the National Academy of Sciences, India, and the National Academy of Medical Sciences, India. Dr. Kumar has received several prestigious awards and has published extensively in high-impact international journals in immunology and translational medicine. Prof. Sanjeev Kumar Gupta is a distinguished surgeon and academician with extensive national and international recognition. He has received several prestigious fellowships, including the Commonwealth Fellowship, Boyscast Fellowship, UICC Fellowship, and Fellowships of the Royal College of Surgeons of Edinburgh and the National Academy of Medical Sciences, India. He has delivered numerous renowned orations and received multiple awards for excellence in surgical education and research. His academic achievements include gold medals and distinctions in medical education and significant contributions to surgical oncology.

Tab Content 6

Countries Available